Introduction: The gastric adenocarcinoma is one of the Her 2 Expression in Gastric Adenocarcinoma elisabete.fernandes@ua.pt

Elisabete Fernandes
Elisabete Fernandes (1,2), Bruno Sarmento (2), Sérgio
Instituto Português de Oncologia do Porto FG, EPE

We describe the development of a ligand targeted HPLC method demonstrates an association efficiency –

Formulation of polymers PLGA, cisplatin were comple

Objective:The aim of this work was the development –

bioactive agents, thereby reducing systemic toxicity.

systems have great potential for drug delivery since

these bioconjugates nanoparticles can bind selectively

were examined by confocal microscopy indicated that

for PLGA-Cisplatin about 30%. Labeled tissue sections

of polymeric nanoparticles with cisplatin encapsulated

HER2 status and survival or the clinical aspects.

HER2 expression on gastric adenocarcinoma from a

tected tumors, and its role as a promising therapeutic approach in advanced cancer. Epithelial growth receptors (EGFR, HER1, HER2, HER3 and HER4) are cell membrane structures whose attraction more and more attention from researchers

advanced, mainly in the molecular aspects that have

infections risk.

eGISTS are extremely rare, with giant tumors being

even rarer. R0 ressection is the treatment of choice for

all EC were positive for sLea, irrespectively of their his

Based on these observations, we have EC patients

(n=7) serum and EC tumours (n=3) for antibodies

against sLeaexpressing proteins.

All EC were positive for sLea, irrespectively of their histological nature but only two patients showed elevated
CA19-9. Moreover, IgG titers, were elevated in EC patients in comparison to the control group. Autoantibodies against sLea-expressing proteins were detected in all cases. Different sLea-glycopatterns were observed for tumours of distinct histological natures.

DISCUSSÃO: This preliminary data suggests that autoantibodies against sLea-expressing proteins hold potential for non-invasive diagnosis in CA19-9 negative cases and sets the rational for future immunoproteomic studies envisaging highly specific EC biomarkers.

HOSPITAL: Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto)

SERVIÇO: (1) Experimental Pathology and Therapeutics Group, Portuguese Institute for Oncology of Porto; (2) INEB, Institute de Engenharia Biomédica da Universidade do Porto University of Porto; (3) Department of Pathology, Portuguese Institute for Oncology of Porto

AUTORES: Elisabete Fernandes (1,2); Andreia Peixoto (1), Manuel Neves (1), Luís Pedro Afonso (3), Lúcio Lara Santos (1) José Alexandre Ferreira (1)

CONTACTO: Elisabete Fernandes

EMAIL: elisabete.fernandes@ua.pt